Release Date: 15/05/19 08:22 Summary: Half Year Results 2019 - Investor Presentation Price Sensitive: Yes Download Document 3.43MB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%